Mitsui Signs Service Agreement With Oncoshot to Build Asia–US Oncology Real-World Data Network
核心洞察
Mitsui & Co. has entered a service agreement with Singapore-based Oncoshot to use its AI-powered clinical data analysis technology for oncology real-world data.
The initiative will connect oncology specialists across the IHH Healthcare network and Asia-Pacific with Memorial Sloan Kettering Cancer Center via the MSK iHub accelerator.
Oncoshot's federated platform anonymizes and structures hospital data into research-ready datasets without moving data outside the institution, addressing privacy and governance limits.
Mitsui & Co., Ltd. (搜索) has entered a service agreement with Oncoshot Pte. Ltd. (搜索) covering the use of Oncoshot's proprietary clinical data analysis technology, in a collaboration intended to standardize oncology clinical data and accelerate pharmaceutical development across Asia and the United States. Oncoshot is a participant in the MSK iHub, a business accelerator program promoting digital healthcare innovation through industry collaborations with Memorial Sloan Kettering Cancer Center (MSK).
Through its collaboration with MSK iHub and related projects, Oncoshot and Mitsui aim to draw on real-world data (RWD) to advance the standardization of oncology clinical data, promote international collaborative research, shorten clinical study timelines, and generate evidence based on diverse patient populations. Participants will include oncology specialists practicing within the IHH Healthcare Berhad (搜索) network — a leading international healthcare provider whose largest shareholder is Mitsui — as well as other oncology specialists in the Asia-Pacific region.
Addressing Fragmented Data and Limited Asian Representation
Demand for clinical data is rising across clinical research, drug discovery, and trial design, according to the announcement. However, much of this valuable data remains fragmented and unstructured within individual healthcare institutions, while privacy regulations and institution-specific data governance requirements can restrict how data is transferred and used. As a result, access to high-quality clinical data, particularly from Asian patient populations, remains limited — reflecting not only challenges in data quality but also the lack of secure, sustainable, and practical mechanisms for data access.
Oncoshot has developed an AI-powered technology that efficiently anonymizes and structures data within healthcare institutions, including electronic medical records and laboratory analysis results, and converts it into research- and drug development-ready datasets without having to move the data out of the institution. According to the companies, this technology has the potential to accelerate the utilization of clinical data while abiding by strict privacy, access and governance constraints.
Standardized Data Models and Knowledge Exchange
MSK has developed a standardized pan-cancer (搜索) data model — the Common Cancer Data Elements (CCDE) — which provides an ontology-driven framework for harmonizing and analyzing oncology outcomes data. Neil J. Shah, MBBS, Assistant Attending Physician at MSK, said: "MSK is excited to partner with Oncoshot and its network of affiliated hospitals across the Asia-Pacific region. Cancer is a global disease, and advancing care requires a deeper understanding of treatment outcomes across diverse patient populations and healthcare systems. This collaboration will help us integrate data across countries, support global oncology research, and generate insights to improve cancer care worldwide."
Dr. Peter Chow, CEO of IHH Healthcare Singapore, described the partnership as "an important step in advancing complex cancer (搜索) care across our network," adding that connecting IHH specialists with institutions such as MSK would "deepen knowledge exchange and strengthen oncology research through the use of clinical data and technologies including AI."
Strategic Rationale and Expansion Plans
Mitsui said the initiative is intended to enhance IHH's corporate value by further advancing the sophistication of its healthcare services, while contributing to greater efficiency and effectiveness in the clinical development of pharmaceuticals through the utilization of clinical data. Under its Medium-term Management Plan 2029, Mitsui has identified "Wellness Ecosystem Creation 2.0" as one of its Key Strategic Initiatives, and is working to expand access to advanced healthcare through IHH and to contribute to pharmaceutical innovation through clinical data utilization.
Yoichiro Endo, Chief Operating Officer of Mitsui's Wellness Business Unit, said: "As progress in pharmaceuticals and other medical technologies continues to drive greater personalization and complexity in healthcare, we are excited by the opportunity to contribute to the advancement of global healthcare by maximizing the value of RWD accumulated in clinical settings, including within IHH, together with technologies such as AI. Through the effective use of data, we aim not only to improve standards of care, but also to accelerate and enhance the efficiency of new drug development."
Endo added that Mitsui intends to expand data collaboration among IHH and leading medical institutions in Japan and across the Asia-Pacific region, and to develop new business opportunities in the United States and other markets at the forefront of pharmaceutical innovation and new drug development.
By utilizing Oncoshot's clinical data platform, Mitsui aims to create an environment in which healthcare professionals across the IHH network can more readily access opportunities for knowledge exchange with leading international research institutions and participate in clinical research activities. Through these efforts, Mitsui said it seeks to support the continued development of medical expertise, expand access to innovative treatment opportunities for patients, and contribute to improving the quality of cancer (搜索) care across the Asia-Pacific region.
Partner Profiles
Oncoshot, headquartered in Singapore and established in 2018, is a digital health company focused on oncology. It provides a secure, federated AI-powered data platform that helps healthcare institutions structure and harmonize oncology clinical data while supporting local data governance and patient privacy, with the aim of promoting the use of real-world data, facilitating clinical research collaboration, and improving access to clinical trial opportunities.
IHH Healthcare Berhad (搜索), headquartered in Kuala Lumpur, Malaysia, and established in 2010, operates 89 hospitals across 10 countries, providing services ranging from advanced specialty care to outpatient, diagnostic, rehabilitation, and home care. Its portfolio includes the Gleneagles, Mount Elizabeth, Parkway, Pantai, Fortis, Acibadem and Prince Court brands. Mount Elizabeth Novena Hospital in Singapore is one of the hospitals within the IHH network participating in the collaboration framework.
MSK, headquartered in New York and established in 1884 as the New York Cancer (搜索) Hospital, is described in the announcement as a leading global cancer center.